Blog

A biotech sponsor engaged an academic CRO (ACRO) to manage data management and biostatistics for an active clinical study, but persistent data quality issues and a deteriorating clean-up cadence placed the program’s integrity at risk. Recognizing the imperative to protect the integrity of study data without disrupting program momentum, the sponsor made a decisive de...

Phase I clinical development is one of the most critical decision points in a novel therapeutic’s journey. Poor planning at this stage leads to hidden costs, regulatory complications, and delayed go/no-go decisions that drain resources and momentum. The pressure to move quickly can lead investigators to overlook essential strategic considerations. These span regulatory pathwa...

Rare liver diseases are challenging indications in clinical development. Conditions such as primary biliary cholangitis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, and Alagille syndrome are defined by low patient prevalence, complex disease biology, and a profound unmet need. The affected populations are small, geographically dispersed, and...

Psychiatry is among the most demanding areas of clinical development. It is defined by persistent unmet needs, elevated placebo response rates, and uniquely complex patient populations that continue to challenge conventional development paradigms. The global burden is large. Nearly one billion individuals around the world are living with mental health disorders. Yet despite t...

A small biotech sponsor needed support for a Phase II study of an antipsychotic therapy in acute schizophrenia. With limited internal clinical operations experience and complex inpatient study design, the sponsor chose Worldwide Clinical Trials for our strong execution and guidance capabilities. This required operational flexibility and rapid scaling. Working as part of the s...